# Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

> **NCT05891080** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 124 (estimated)

## Conditions studied

- Stage III Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** JS004
- **DRUG:** Pemetrexed
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT05891080
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891080, "Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05891080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*